Figure 1.
Article selection diagram for meta-analysis.
Table 1.
Characteristics of head to head RCT studies of GLP-1 analogues and Sitagliptin included in the meta-analysis.
Figure 2.
+, Low risk of bias; − high risk of bias; ?, unknown risk of bias. Risk of bias assessment for random sequence generation and allocation concealment is performed at the study level. Risk of bias assessment for blinding of participants and personnel, incomplete outcome data, selective reporting, and overall risk of bias are for the primary outcome (change in HbA1c).
Figure 3.
Meta-analysis of change in HbA1C (%) in included trials using random effects model.
Table 2.
Summary of Meta-analyses of Outcomes in Patients with Type 2 Diabetes treated With GLP-1 analogues vs Sitagliptin.
Figure 4.
Meta-analysis of change in Fasting Plasma Glucose (mmol/L) in included trials using random effects model.
Figure 5.
Meta-analysis of change in body weight (kg) of included trials using random effects model.
Table 3.
Summary of meta-analyses of adverse events in patients with type 2 diabetes treated with GLP-1 analogues vs Sitagliptin.